^
    Back
    Association details:
    Biomarker:OTUD6B expression + MYC expression
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    AACR 2022
    Title:

    2298 / 2 - OTUD6B is a dependency in multiple myeloma that drives S-phase entry via MYC activation

    Published date:
    03/09/2022
    Excerpt:
    Multiple myeloma (MM)...To identify new vulnerabilities in MM...OTUD6B expression was found to strongly correlate with MYC expression and significantly reduced progression-free survival in patients treated with the PI bortezomib